We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

New Antibodies Could Mitigate Opioid Side Effects

Antibodies.
Credit: iStock.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

Summary 

Scientists from the University of Geneva developed a nanobody, NbE, that binds tightly to opioid receptors, blocking their activity. This could mitigate the severe side effects of opioids and lead to the creation of smaller, more effective molecules. These findings have implications for managing opioid overdoses.

Key Takeaways 

  • Nanobody Discovery: NbE effectively binds to opioid receptors, preventing opioids from exerting their effects.
  • Potential Treatment Improvement: Smaller molecules derived from NbE could provide better options than current treatments like naloxone.
  • Aim for Safer Opioid Use: The research seeks to reduce the risks and side effects associated with opioid medications, addressing the global health crisis.

  • Opioid drugs are highly effective at relieving pain but come with severe drawbacks. Their side effects range from dizziness to potentially fatal respiratory depression. Their illegal use contributes to nearly half a million deaths worldwide each year. Researchers from the University of Geneva (UNIGE) have discovered a molecule, called nanobody NbE, which binds tightly and durably to the cell receptors that usually bind to opioids, thereby blocking the drugs’ activity. Moreover, the scientists were able to create even smaller molecules that retain the same properties, which could prove far more effective than current treatments in mitigating the harmful effects of opioids. These findings are published in the journal Nature Communications.


    Opioids are a large family of pharmaceuticals that include morphine, fentanyl and tramadol. These powerful drugs are mainly used as painkillers, but also trigger a euphoric effect by interacting with nerve cells in the brain. However, they are very addictive and produce dangerous side effects. Diverted from their original use, natural and synthetic opioids have become the deadliest drugs in the United States, and this global health crisis is now threatening Europe.

    Our new molecules have the potential to reverse or reduce the deleterious side effects of opioids.

    “We need to urgently develop new molecules to better mitigate the side effects for patients and manage the risks of opioid-related overdoses”, explains Miriam Stoeber, associate professor in the Department of Cell Physiology and Metabolism at UNIGE Faculty of Medicine, who initiated and coordinated the project. “To understand how a molecule works, we need to know how it affects the brain cells. In our study, we used tiny natural proteins derived from llama antibodies, called nanobodies, designed to bind specifically to the target receptor on the cell’s surface.”

    Want more breaking news?

    Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

    Subscribe for FREE

    The strong binding power of nanobody NbE

    UNIGE researchers have found that NbE, one of the nanobodies under study, has the unique ability to bind so tightly and durably to specific opioid receptors that it prevents opioids from binding to these same receptors, therefore blocking the drug’s activity. “To determine how NbE binds to its target, we used high resolution structural biology methods, thanks to the new Dubochet Centre for Imaging”, describes Andreas Boland, assistant professor in the Department of Molecular and Cellular Biology at UNIGE Faculty of Science, and co-last author of the study. “We identified a unique binding mode where only a small portion of the nanobody is responsible for its correct receptor selectivity. Knowing precisely which part of the nanobody is at stake allows us to imagine new ways to induce the same effects with pharmaceuticals.”

    Small molecules, large effects

    While significantly smaller than antibodies, nanobodies remain quite large. They can be costly to produce and may not fully reach the target tissue in the body. In collaboration with the Prof. Steven Ballet team from the University of Brussels, the UNIGE research team synthesised in vitro a set of even smaller molecules mimicking the key part of NbE responsible for the selected binding to opioid receptors. “By durably blocking opioid receptors, our new molecules have the potential to reverse or reduce the deleterious side effects of opioids. In case of overdose, they could provide a better, longer lasting option than naloxone, the treatment currently in use. We will now refine their structure to improve even further their efficiency and facilitate their delivery to the targeted nerve cells in the brain”, concludes Miriam Stoeber.


    Reference: Yu J, Kumar A, Zhang X, et al. Structural basis of μ-opioid receptor targeting by a nanobody antagonist. Nat Commun. 2024;15(1):8687. doi: 10.1038/s41467-024-52947-6


    This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.


    This content includes text that has been generated with the assistance of AI. Technology Networks' AI policy can be found here.